Bluebird, after delays, gets speedy FDA review for beta thalassemia gene therapy
November 22, 2021Despite Positive Phase II Data, Connect Derm Drug Faces Tough Market
November 22, 2021Connect Biopharma shares plummeted 55% despite reported positive topline data from its Phase II trial of CBP-201 for adults with moderate-to-severe atopic dermatitis.
